Fig 1: (A) Analysis of RNA-Seq data from TCGA Pan-cancer analysis with mean value for the FPKM for each cancer type and each cadherin family member. (B) RNA-seq from CTCs enriched from whole blood with the iChip microfluidic device and isolated as single cells. Expression values represent log10(RPM+1). Gray horizontal lines demarcate individual patients. (C) Three-dimensional modeling of the top two docking sites of the antigen binding region (ribbon model) of the 23C6 antibody on the extracellular domain of CDH11 (space filling model). Upper: Binding free energy difference (ΔE) = −46.4 and Lower model with ΔE = −32.6. (D) Protein sequence alignment using Clustal omega of the two docking sites of the 23C6 antibody on CDH11 compared to the protein sequences for CDH1. Colors represent amino acid properties: Red, identical amino acids; orange, conserved amino acids with combined strongly and weakly similar properties. (E) Western blot analysis of recombinant purified hCDH1, hCDH11 and mCDH1 proteins detected with 23C6 antibody or a CDH11 specific antibody 3H10. “h” indicates human and “m” indicated murine. Loading control with Ponceau staining. High molecular weight bands likely represent aggregation of the highly purified proteins. (F) H&E staining (Left) and 23C6 immunohistochemical staining (Right) of representative sections of two different tumors from a breast cancer tumor array. Upper right scored as 3+ for tumor cell membrane staining. Lower right scored as 1+ for tumor cell membrane staining. (G) Distribution (Upper) and breakdown in ER positive and negative tumors (Lower) of membranous staining intensity on a scale of 0 (no staining) to 3+ (intense staining). (H) Analysis of RNA-Seq data from TCGA Pan-cancer analysis of whole genomes with mean value for the FPKM for CDH1 and CDH11. Error bars represent SD. (I) RNA-seq from single cell CTCs enriched from whole blood from metastatic breast cancer patients. (Left) Proportion of patients with average expression of the combined sum of CDH1 and CDH11 in the indicated ranges. (Right) Proportion of CTCs with >5 RPM expression of CDH1 and CDH11 within individual patients.